Key stats
About Fidelity Disruptive Medicine ETF
Home page
Inception date
Jun 12, 2023
Structure
Open-Ended Fund
Distributes
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Tax on distributions
Qualified dividends
FMED seeks long-term capital appreciation by utilizing proprietary disruptive strategies in identifying companies involved in disruptive technologies for its portfolio. Disruptive technologies are innovations that may reshape how businesses currently deliver their services and operate, potentially displacing industry leaders over time. The fund primarily invests in growth and value stocks of companies tied with disruptive innovation in health care globally. This includes robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based healthcare platforms, advanced diagnostics, and consumer wellness. The adviser uses fundamental analysis, as well as economic and market conditions for its portfolio construction. The adviser may buy, sell, and hold decisions at their discretion. FMED converted from a mutual fund to an actively managed ETF, with $44 million in assets.
Classification
What's in the fund
Exposure type
Health Technology
Stock breakdown by region
Displays a symbol's price movements over previous years to identify recurring trends.